Comparison of Prognostic Usefulness of Serum Insulin-Like Growth Factor-Binding Protein 7 in Patients With Heart Failure and Preserved Versus Reduced Left Ventricular Ejection Fraction

Camilla Hage (1) , Mette Bjerre (2) , Jan Frystyk (2) , Harvest F. Gu (1) , Kerstin Brismar (1) , Erwan Donal (3, 4) , Jean-Claude Daubert (5, 4) , Cecilia Linde (1) , Lars H. Lund (1)

1 Karolinska Institutet [Stockholm]
2 Aarhus University Hospital
3 Service de cardiologie et maladies vasculaires [Rennes] = Cardiac, Thoracic, and Vascular Surgery [Rennes]
4 CIC-IT Rennes
5 CHU Pontchaillou [Rennes]

We aimed to characterize of the role of insulin-like growth factor-binding protein 7 (IGFBP-7) in heart failure (HT) pathophysiology. IGFBP-7 has been associated with cardiac hypertrophy and diastolic dysfunction in HF. In 86 patients with HF with a preserved ejection fraction (HFpEF) (ejection fraction [EF] >= 45%) and 79 with HF with a reduced ejection fraction (HFrEF), we assessed concentrations of serum IGFBP-7, correlations between serum IGFBP-7 and clinical data, diastolic function, and associations with outcome. IGFBP-7 was lower in HFpEF than HFrEF (102 vs 152 mu g/L, p <0.001) and correlated with New York Heart Association class (HFpEF r = 0.25, p = 0.020; HFrEF r = 0.26, p = 0.022), N-terminal pro brain natriuretic peptide (NT-proBNP) (HFpEF r = 0.53, p <0.001; HFrEF r = 0.50, p <0.001), and estimated glomerular filtration rate (eGFR) (HFpEF r = 0.47, p <0.001; HFrEF r = 0.45, p <0.001). In IfFpEF, IGFBP-7 correlated with E/e' (r = 0.31, p = 0.012) and E/A ratio (r = 0.31, p = 0.011). In HFrEF, but not HFpEF, IGFBP-7 correlated with age (r = 0.29, p = 0.009) and atrial fibrillation (r = 0.34, p = 0.002). IGFBP-7 predicted the outcome in HFpEF (hazard ratio 4.19 [1.01 to 17.35], p = 0.048]) but not in HFrEF (0.72 [0.24 to 2.14], p = 0.554). In conclusion in HFrEF, IGFBP-7 was elevated and associated with HF severity but not prognostic, suggesting a marker of risk. In HFpEF, IGFBP-7 was less elevated but associated with markers of diastolic dysfunction, HF severity, and prognosis. IGFBP-7 may contribute to the progression of HFpEF possibly through inflammation and oxidative stress. (C) 2018 Elsevier Inc. All rights reserved.

Domains: Life Sciences [q-bio]; Bioengineering; Life Sciences [q-bio]; Human health and pathology; Cardiology and cardiovascular system

Camilla Hage, Mette Bjerre, Jan Frystyk, Harvest F. Gu, Kerstin Brismar, et al.. Comparison of Prognostic Usefulness of Serum Insulin-Like Growth Factor-Binding Protein 7 in Patients With Heart Failure and Preserved Versus Reduced Left Ventricular Ejection Fraction. American Journal of Cardiology, 2018, 121 (12), pp.1558-1566. ⟨10.1016/j.amjcard.2018.02.041⟩. ⟨hal-01874526⟩